PharmiWeb.com - Global Pharma News & Resources

Clinical trials - Press Releases

Date Title Company
11-Oct-2022 Clariness Selects Lacework to Future Proof Cloud Security Lacework
10-Oct-2022 HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China HUTCHMED
07-Oct-2022 Paradigm Clinical Research Names Industry Veteran Kurt Mussina as CEO as Expansion Plans Are Set in Motion Paradigm Clinical Research
05-Oct-2022 atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT atai Life Sciences N.V.
04-Oct-2022 Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease Freeline Therapeutics
29-Sep-2022 Dr. Vince Clinical Research Opens Industry-Leading Clinical Pharmacology Unit Dr. Vince Clinical Research
28-Sep-2022 Avance Clinical Wins International Health Award for Biotech CRO Services Avance Clinical
27-Sep-2022 Quanticate partners with Cancer Research UK to launch DETERMINE Study Quanticate
26-Sep-2022 TolerogenixX Publishes Three-Year Follow-Up Data from Phase I Trial of Immune Tolerance-Inducing MIC-Lx Cell Therapy TolerogeniXx GmbH
26-Sep-2022 TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer TILT Biotherapeutics
22-Sep-2022 Data presented today show more participants achieved greater treatment satisfaction when switching to once-weekly insulin icodec in ONWARDS 2 trial Novo Nordisk
22-Sep-2022 Spexis announces positive renal impairment clinical trial results with balixafortide Spexis AG
20-Sep-2022 Rapid growth puts Australian CRO Accelagen on the map for clinical research globally Accelagen
15-Sep-2022 Novotech presented with Cell & Gene Excellence Award 2022 at 6th Cell & Gene Therapy World Asia Conference Novotech Health Holdings Pte Ltd
13-Sep-2022 Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress Zymeworks
13-Sep-2022 NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022 NuCana
12-Sep-2022 Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd
12-Sep-2022 Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022 Transgene
12-Sep-2022 Almirall: Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Phase 3 Monotherapy Atopic Dermatitis Trials Almirall
12-Sep-2022 Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022 Anaveon